• Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors 

      Anthiya, Shubaash; Oztürk, Süleyman Can; Yanik, Hamdullah; Tavukcuoglu, Ece; Sahin, Adem; Datta, Dhrubajyoti; Charisse, Klaus; Álvarez, David Moreira; Loza, María Isabel; Calvo, Alfonso; Sulheim, Einar; Loevenich, Simon; Klinkenberg, Geir; Schmid, Ruth Baumberger; Manoharan, Muthiah; Esendağlı, Güneş; Jose Alonso, Maria (Peer reviewed; Journal article, 2023)
      K-RAS is a highly relevant oncogene that is mutated in approximately 90% of pancreatic cancers and 20–25% of lung adenocarcinomas. The aim of this work was to develop a new anti-KRAS siRNA therapeutic strategy through the ...